Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:2413

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles

(Circulation. 2005;111:2413.)
© 2005 American Heart Association, Inc.

Issue Highlights


*    POSTINFARCTION GENE THERAPY AGAINST TRANSFORMING GROWTH FACTOR-ß SIGNAL MODULATES INFARCT TISSUE DYNAMICS AND ATTENUATES LEFT VENTRICULAR REMODELING AND HEART FAILURE, by Okada et al.
up arrowTop
*POSTINFARCTION GENE THERAPY...
down arrowREGENERATION OF INFARCTED...
down arrowLOWER SERUM SODIUM IS...
down arrowLONG-TERM RESULTS OF MITRAL...
down arrowCardiology Patient Page
down arrowImages in Cardiovascular...
down arrowCorrespondence
 


*    REGENERATION OF INFARCTED MYOCARDIUM BY INTRAMYOCARDIAL IMPLANTATION OF EX VIVO TRANSFORMING GROWTH FACTOR-ß–PREPROGRAMMED BONE MARROW STEM CELLS, by Li et al.
up arrowTop
up arrowPOSTINFARCTION GENE THERAPY...
*REGENERATION OF INFARCTED...
down arrowLOWER SERUM SODIUM IS...
down arrowLONG-TERM RESULTS OF MITRAL...
down arrowCardiology Patient Page
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
The clinical benefit of limiting ventricular remodeling after myocardial infarction is clear, though the pharmacological tools we have available are only moderately successful. Future therapies targeting the underlying biology of the remodeling process appear promising, although as 2 articles in this week’s Circulation illustrate, ‘the devil is in the details.’ Tissue growth factor ß (TGF ß) promotes fibroblast proliferation and scar formation, and a study by Okada et al suggests that blocking its action in the heart will improve outcome after infarction. On the other hand, Li et al demonstrate that the same growth factor has a beneficial effect on bone marrow stem cells, improving their ability to differentiate into myocytes and repair the wounded heart. Careful evaluation of these and other biologically based therapeutic strategies have the potential to lead us to the next era in management of the postinfarction patient. See pp 2430 and 2438.


*    LOWER SERUM SODIUM IS ASSOCIATED WITH INCREASED SHORT-TERM MORTALITY IN HOSPITALIZED PATIENTS WITH WORSENING HEART FAILURE: RESULTS FROM THE OUTCOMES OF A PROSPECTIVE TRIAL OF INTRAVENOUS MILRINONE FOR EXACERBATIONS OF CHRONIC HEART FAILURE (OPTIME-CHF) STUDY, by Klein et al.
up arrowTop
up arrowPOSTINFARCTION GENE THERAPY...
up arrowREGENERATION OF INFARCTED...
*LOWER SERUM SODIUM IS...
down arrowLONG-TERM RESULTS OF MITRAL...
down arrowCardiology Patient Page
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Hyponatremia was identified years ago as a powerful predictor of an unfavorable prognosis in patients with heart failure, originally in patients with severe reduction in serum sodium. In this issue of Circulation, a retrospective analysis of 949 patients admitted to hospital with decompensated heart failure in the OPTIME-CHF trial by Klein and colleagues demonstrates that even modest degrees of reduction in serum sodium were associated with a significantly elevated risk of unfavorable outcomes, including number of days in hospital within 60 days of randomization, as well as in-hospital and 60-day mortality. Moreover, the results were seen in the setting of substantial use of angiotensin-converting enzyme inhibition or angiotensin receptor blockers. These data suggest that a simple clinical measurement can identify a group with very high short-term risk among patients admitted to hospital with heart failure in the contemporary treatment era. See p 2454.


*    LONG-TERM RESULTS OF MITRAL VALVE REPAIR IN ACTIVE ENDOCARDITIS, by Zegdi et al.
up arrowTop
up arrowPOSTINFARCTION GENE THERAPY...
up arrowREGENERATION OF INFARCTED...
up arrowLOWER SERUM SODIUM IS...
*LONG-TERM RESULTS OF MITRAL...
down arrowCardiology Patient Page
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Mitral valve endocarditis requiring surgical therapy can be treated by valve replacement or mitral valve repair. A variety of repair techniques can be used to reconstruct the valve tissue and remove the site of active infection. In their article, Dr Alain Carpentier’s group in Paris reported having 37 patients undergo a mitral valve repair for active endocarditis. During a 5-year period, these repair patients represented 75% of the total mitral valve operations performed for active endocarditis, demonstrating a high degree of repair feasibility. The operative mortality was low (3%), and the 10-year survival rate was 96%, with 92% having trivial to no mitral regurgitation on echocardiography. Freedom from mitral valve reoperation at 10 years was 91%, and recurrence of endocarditis was 3%. These excellent results should allow clinicians to consider mitral valve repairs as an alternative to replacement for mitral valve endocarditis. See p 2532.

Visit www.circ.ahajournals.org:


*    Cardiology Patient Page
up arrowTop
up arrowPOSTINFARCTION GENE THERAPY...
up arrowREGENERATION OF INFARCTED...
up arrowLOWER SERUM SODIUM IS...
up arrowLONG-TERM RESULTS OF MITRAL...
*Cardiology Patient Page
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Homocysteine and MTHFR Mutations: Relation to Thrombosis and Coronary Artery Disease. See p e289.


*    Images in Cardiovascular Medicine
up arrowTop
up arrowPOSTINFARCTION GENE THERAPY...
up arrowREGENERATION OF INFARCTED...
up arrowLOWER SERUM SODIUM IS...
up arrowLONG-TERM RESULTS OF MITRAL...
up arrowCardiology Patient Page
*Images in Cardiovascular...
down arrowCorrespondence
 
Continuous Cardiac Magnetic Resonance Imaging During Untreated Ventricular Fibrillation. See p e294.Down



View larger version (134K):
[in this window]
[in a new window]
 

ST-Segment Elevation Due to Hyperkalemia. See p e295.


*    Correspondence
up arrowTop
up arrowPOSTINFARCTION GENE THERAPY...
up arrowREGENERATION OF INFARCTED...
up arrowLOWER SERUM SODIUM IS...
up arrowLONG-TERM RESULTS OF MITRAL...
up arrowCardiology Patient Page
up arrowImages in Cardiovascular...
*Correspondence
 
See p e297.


Related Articles:

Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study
Liviu Klein, Christopher M. O’Connor, Jeffrey D. Leimberger, Wendy Gattis-Stough, Ileana L. Piña, G. Michael Felker, Kirkwood F. Adams, Jr, Robert M. Califf, Mihai Gheorghiade for the OPTIME-CHF Investigators
Circulation 2005 111: 2454-2460. [Abstract] [Full Text]

Postinfarction Gene Therapy Against Transforming Growth Factor-ß Signal Modulates Infarct Tissue Dynamics and Attenuates Left Ventricular Remodeling and Heart Failure
Hideshi Okada, Genzou Takemura, Ken-ichiro Kosai, Yiwen Li, Tomoyuki Takahashi, Masayasu Esaki, Kentaro Yuge, Shusaku Miyata, Rumi Maruyama, Atsushi Mikami, Shinya Minatoguchi, Takako Fujiwara, and Hisayoshi Fujiwara
Circulation 2005 111: 2430-2437. [Abstract] [Full Text]

Long-Term Results of Mitral Valve Repair in Active Endocarditis
Rachid Zegdi, Mohamed Debièche, Christian Latrémouille, Djoulène Lebied, Catherine Chardigny, Jean-Michel Grinda, Sylvain Chauvaud, Alain Deloche, Alain Carpentier, and Jean-Noël Fabiani
Circulation 2005 111: 2532-2536. [Abstract] [Full Text]

Regeneration of Infarcted Myocardium by Intramyocardial Implantation of Ex Vivo Transforming Growth Factor-ß–Preprogrammed Bone Marrow Stem Cells
Tao-Sheng Li, Masanori Hayashi, Hiroshi Ito, Akira Furutani, Tomoaki Murata, Masunori Matsuzaki, and Kimikazu Hamano
Circulation 2005 111: 2438-2445. [Abstract] [Full Text]

Homocysteine and MTHFR Mutations: Relation to Thrombosis and Coronary Artery Disease
Elizabeth A. Varga, Amy C. Sturm, Caron P. Misita, and Stephan Moll
Circulation 2005 111: e289-e293. [Full Text]

Continuous Cardiac Magnetic Resonance Imaging During Untreated Ventricular Fibrillation
Vincent L. Sorrell, Maria I. Altbach, Karl B. Kern, Scott Squire, Ronald W. Hilwig, Melinda M. Hayes, Gordon A. Ewy, and Robert A. Berg
Circulation 2005 111: e294. [Full Text]

ST-Segment Elevation Resulting From Hyperkalemia
Daniel B. Sims and Laurence S. Sperling
Circulation 2005 111: e295-e296. [Full Text]

Letter Regarding Article by Shyu et al, "Functional Recovery of Stroke Rats Induced by Granulocyte Colony-Stimulating Factor–Stimulated Stem Cells" Response
Ivo R. Buschmann, Konstantin-Alexander Hossmann, Woei-Cherng Shyu, Shinn-Zong Lin, Hui-I Yang, Cheng-Yoong Pang, Pao-Sheng Yen, Yi-Shiuan Tzeng, and Hung Li
Circulation 2005 111: e297-e298. [Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles